Loading...
Risk Assessment generated by a regulatory process (RA)
  |  
BCH-RA-BR-299896-1   |   PDF   |   Print   |  
last updated: 09 Jul 2026
General Information
Risk assessment of the PROTEQFLU Vaccine - Technical Opinion No. 5486/2017.
EN
08 Jun 2017
Risk assessment details
  • Proteqflu - equine influenza vaccine
    | Merial | Production of medical or pharmaceutical compounds (human or animal) (Vaccines), Use as vaccine
ProteqFlu is a vaccine intended to protect domestic horses against equine influenza (H3N8).
EN
Methodology and points to consider
There is no potential environmental hazard that can be identified by using the ProteqFlu vaccine.
EN
Safety studies were conducted on non-target species involving canaries, ducks, chickens, pigs, rats and guinea pigs and the results support the product's safety profile.
EN
There is no potential environmental hazard that can be identified by using the ProteqFlu vaccine.
EN
It is not potentially causing significant environmental degradation or harmful to human health.
EN
The analysis of the experimental data presented in the present request show that the GMOs in question are harmless to other species of animals, to man and to the environment.
EN
The ProteqFlu vaccine is not potentially risk-causing.
EN
The ProteqFlu vaccine, CTNBio concluded that the present request complies with the pertinent norms and legislation that aim to guarantee the biosafety of the environment, agriculture, human and animal health.
EN
Molecular traditional methods. 
EN
Information sharing with other databases
Yes
No
No
Additional information
EN
Records referencing this document Show in search
Record type Field Record(s)
Country's Decision or any other Communication Risk assessment 1